We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Lightweight Cardiac-Assist System

By HospiMedica staff writers
Posted on 01 Aug 2006
A third-generation cardiac-assist system has been designed as a permanent alternative to a heart transplant for patients suffering from heart failure. More...


The VentrAssist system, manufactured by Ventracor (Chatswood, NSW, Australia), is a third-generation left-ventricle-assist device (LVAD) system designed to provide patients suffering from heart failure with better quality of life. It can also be used as a bridge to heart transplant and possibly as a bridge to recovery, where it may allow a deteriorating heart an opportunity to recuperate. The CE Mark trial has been completed, and preparations are underway for a European market launch.

The system is comprised of a blood pump that connects to the left ventricle of the diseased heart to help the ailing heart's pumping function and has only one moving part -- a hydrodynamically suspended impeller. The impeller has been designed to have no wearing parts or cause blood damage. Additionally, the system has a fully redundant back-up motor drive, controller, and processor. It weighs just 298 grams and measures 60 mm in diameter, making it suitable for both children and adults. The implanted parts of the VentrAssist system use materials that are fully biocompatible, including titanium alloys, and its components are light, strong, non-toxic, and highly resistant to degradation within the body.

The company has announced that more than 50 devices have been implanted worldwide, and that it is the only company with a third-generation LVAD in clinical trials in the United States. The baseline results and cost effectiveness (BRACE) report will add to the body of evidence for the performance of the device in up to 10 new centers in Europe, in addition to the current Australian, New Zealand, and European sites.



Related Links:
Ventracor

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
IV Therapy Cart
Avalo I.V Therapy Cart
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.